Changes in serum hepatitis C virus RNA in interferon nonresponders retreated with interferon plus ribavirin: A preliminary report

Journal of Clinical Gastroenterology

Volumn 28, Issue 4, 1999, Pages 313-316

  Nyberg, Lisa ^a   Albrecht, Janice ^b   Glue, Paul ^b   Gianelli, Gianluigi ^a   Zambas, Demetris ^b   Elliot, Michael ^b   Conrad, A ^c   McHutchison, John G ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c National Genetics Institute   (United States)

Author keywords

Combination therapy; Interferon; Ribavirin; Serum HCV RNA

Indexed keywords

ALPHA INTERFERON; INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MALE; ORAL DRUG ADMINISTRATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RNA ANALYSIS; RNA SYNTHESIS; SERODIAGNOSIS; TREATMENT OUTCOME; VIRUS LOAD; VIRUS TITRATION;

ADULT; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; MALE; MIDDLE AGED; PILOT PROJECTS; POLYMERASE CHAIN REACTION; RIBAVIRIN; RNA, VIRAL; TIME FACTORS; TREATMENT OUTCOME; VIRAL LOAD; VIREMIA;

EID: 0033033697     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-199906000-00006     Document Type: Article

References (24)

1. Hoofnagle JH, DiBisceglie AM. The treatment of chronic viral hepatitis. N Engl J Med 1997;336:347-56.
2. Tine F, Magrin S, Craxi A, Pagliaro L. Interferon for non-A, non-B hepatitis: a meta-analysis of randomized clinical trials. J Hepatol 1991;13:192-9.
3. Marcellin P, Boyer N, Giostra E, et al. Recombinant human alpha-interferon in patients with chronic non A, non B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991;13:393-7.
4. Causse X, Godinot H, Chevallier M, et al. Comparison of 1 or 3 MU of interferon alpha-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991;101:497-502.
5. Saracco G, Rosina F, Abate ML, et al. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alpha 2b. Hepatology 1993;18:1300-5.
6. Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;332:1457-62.
7. DiBisceglie AM, Shindo M, Fong T-S, et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992;16: 649-54.
8. Dusheiko G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996;25:591-8.
9. Camps J, Garcia N, Rieza-Boj J, Civiera M, Prieto J. Ribavirin in the treatment of chronic hepatitis C unresponsive to alfa interferon. J Hepatol 1993;19:408-12.
10. DiBisceglie AM, Conjeevaram HS, Fried MW, et al. Ribavirin as therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:897-903.
11. Bodenheimer HC, Lindsay KL, Davis GL, Lewis JH, Thung SN, Seef LB. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 1997;26:473-7.
12. Schalm S, Hansen B, Chemello L, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. J Hepatol 1997;26:961-6.
13. Reichard O, Schvarcz R, Weiland O. Therapy of hepatitis C: interferon and ribavirin. Hepatology 1997;26(Suppl 1):1085-115.
14. Reichard O, Norkraus E, Fryden A, Braconier J-H, Sonnerborg A, Weiland O. Randomized, double-blind, placebo-controlled trial of interferon α-2b with and without ribavirin for chronic hepatitis C. Lancet 1988;351:83-7.
15. Patterson J, Fernandez-Larson R. Molecular action of ribavirin. Rev Infect Dis 1990;12:1132-46.
16. Ning Q, Brown D, Parodo J, et al. Ribavirin inhibits viral induced macrophage production of tumor necrosis factor, interleukin 1 and procoagulant activity and preserves Th1 cytokine production but inhibits Th2 cytokine response. J Immunol 1998;160:3487-93.
17. Hultgren C, Milich DR, Weiland O, Sallberg M. The antiviral compound ribavirin modulates T helper (Th)1/Th2 subset balance in hepatitis B and C virus-specific immune responses. J Gen Virol 1998;79:2381-92.
18. Sherlock S. Antiviral therapy for chronic hepatitis C viral infection. J Hepatol 1995;23(Suppl 2):3-7.
19. Tong MJ, Blatt LM, McHutchison JG, Co RL, Conrad A. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology 1997;26:1640-5.
20. Stuyver I, Rossau R, Wyseur A, et al. Typing of hepatitis C virus isolates and characterization of new subtypes using a line probe assay. J Gen Virol 1993;74:1093-102.
21. Nguyen TT, Vaziri A, Pockros PJ, et al. Fluctuations in viral load (HCV RNA) are relatively insignificant in untreated patients with chronic HCV infection. J Viral Hepatitis 1996;3:75-8.
22. 2, rimantadine hydrochloride and ribavirin inhibition of influenza virus replication in vitro. Antimicrob Agents Chemother 1984;25:53-7.
23. Zeuzem S, Schmidt JM, Lee J-H, Rüster B, Roth WK. Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996;23:366-71.
24. Lam NP, Neumann AV, Gretch DR, Wiley TE, Perelson AS, Layden TJ. Dose-dependent acute clearance of hepatitis C genotype I virus with interferon alfa. Hepatology 1997;26:226-31.